Home > Formulary : Adult > Recent Decisions > 2020 >
Decisions 2nd June 2020
At the meeting on the 2nd June the following decisions were agreed
New Drug Requests
Approved
Dalbavancin (TLS Red)
- On the advice of Microbiology or Infectious Disease Physician to be used within it’s licensed indication for the treatment of complicated and potentially life-threatening bacterial infections in adult populations, where the organism is proven sensitive to Dalbavancin and other agents have failed or bacterial organism has shown resistance to other agents.
Triptorelin (Decapeptyl®) (TLS Amber no SCP)
- 6 monthly formulation added to formulary for Prostate Cancer indication in line with licensed indications. 6 monthly formulation is preferred in Primary Care once a tolerance with patient has been established following a trial of 1m or 3m formulation.
- Triptorelin remains the first line GnRH analogue of choice on the formulary for licensed indications
Leuprorelin (Prostap®) (TLS Amber no SCP)
- approved as second line GnRH analogue of choice on the formulary for licensed indications
(TLS Amber 3 months)
Shared Care Protocols/TLS changes
Mycophenolate mofetil Mycophenolate sodium (TLS Amber 3 months)
- TLS change from Red to Amber 3 month for use in rheumatological conditions
- JFG confirmed TLS Amber 3 month appropriate for this medication which has not previously been prescribed in Primary Care
Levetiracetam (parenteral) (TLS Amber no SCP)
- For palliative patients, under the advice of a specialist palliative care consultant, who are unable to take their oral antiepileptics to treat seizures.
Further Work Needed
Desmopressin Oral Lyophilisate (Noqdirna®) (TLS Amber 3 months)
- New Drug Request approved for inclusion to the formulary, pending SCP, for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria